Navigation Links
Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
Date:12/8/2012

a treatment associated with both short- and long-term toxicities.

ALL, the most common form of leukemia in children, is a fast-growing cancer of the white blood cells in which the bone marrow makes a large number of abnormal white blood cells that are unable to develop and fight infection. Important developments over the past 20 years have led to seminal insights about ALL in children, and today nearly 90 percent of children diagnosed with standard-risk ALL are cured. Some treatment regimens for standard-risk ALL include initial infusions of daunorubicin, a type of anthracycline. While effective, continual use of this therapy is associated with potential long-term heart damage, leading researchers to assess whether eliminating or reducing the dosage of daunorubicin during the initial one-month induction therapy period might provide the same level of efficacy as the standard treatment protocol with reduced long-term risk.

In order to assess the efficacy of ALL treatment without daunorubicin during induction therapy, a team of researchers from 20 centers across France and one center in Belgium initiated a multicenter Phase III clinical trial in which 1,128 pediatric patients with standard-risk B-cell ALL were randomized into two treatment arms. Arm A included 560 patients who received a standard dose of daunorubicin during induction therapy, while Arm B included 568 patients who did not receive initial therapy with daunorubicin. Both groups received doxorubicin during delayed intensification (last treatment phase before reaching maintenance) and a standard protocol of 24-month maintenance therapy from December 2000 to June 2010, during which five-year event-free survival (EFS) and overall survival (OS) were assessed.

For those patients treated with daunorubicin, the five-year EFS rate was 92.9 percent, compared to 93.3 percent in the non-daunorubicin arm. Overall survival rates were 97.2 percent and 98.2 percent in the daunorubicin and n
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting
2. Benefit6 Whole Body Protection, a New Product by I Do Strive LLC, Provides Increased Energy Production According to Recent Studies
3. Sharp spike in computer-related injuries predicted for medical workers, find studies
4. Analysis of conflicting fish oil studies finds that omega-3 fatty acids still matter
5. Studies from 2012 Quality Care Symposium highlight findings in improving quality of cancer care
6. New studies show effects of mammography guideline changes
7. 2 NIH studies show power of epidemiology research; Underscore need to address health disparities
8. Scripps studies show community-based diabetes programs are key to lowered costs and improved care
9. Cancer Drug Reduced Relapses in MS Patients: Studies
10. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
11. Studies Show Limits, Promise of Laser Removal of Tattoos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... November 22, 2014 Setria® Glutathione ... (TGA) approved it for use “as a therapeutically ... listed within the Therapeutic Goods (Listing) Notice 2014 ... Kyowa Hakko’s Setria® Glutathione will be exclusivity distributed ... that sources and imports fine chemicals to Australian ...
(Date:11/22/2014)... 22, 2014 In order to provide better ... of cocktail party dresses. The business knows that a suitable ... occasions. , Now, the party dresses supplier’s high ... off. As the leading company in fashion industry, LunaDress understands ... for every customer. So it always raises the professional level ...
(Date:11/22/2014)... November 22, 2014 A petition seeking ... http://www.morcellatorlawsuit2015.com ) in minimally-invasive hysterectomies and fibroid removal ... the end of October, Bernstein Liebhard LLP reports. ... as of November 21st, 2014. That represents an increase ... had signed on to the campaign.* , The campaign ...
(Date:11/22/2014)... November 22, 2014 The topic of ... of block retaining walls. The article states that, “While they ... several necessary steps that go into creating this powerful look.” ... a retaining wall is choosing which kind of block matches ... , B&D Rockeries says, “The two main options are concrete ...
(Date:11/22/2014)... Hastings and Hastings, a discount accident ... providing clients with the option of leaving an online ... flexible, intuitive and easy to navigate website that has ... Google + allows clients to research the Hastings and ... informed decision when retaining an attorney. Those who have ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3
... Events, DUBLIN, Ohio, April 8, 2008 Cardinal Health,Inc. ... services that improve,the safety and productivity of health care, plans ... prior to the opening of trading,on the New York Stock ... call for May 1 at,8:30 a.m. EDT to discuss results ...
... impact on childhood anxieties changes during adolescence, study found , , ... drive common fears, and new study finds, but the impact ... almost 2,500 twins born in Sweden from 1985 to 1986. ... ages 8 to 9, ages 13 to 14, ages 16 ...
... new study finds no effect , , TUESDAY, April 8 ... prevent relapses in patients with Crohn,s disease, concluded two ... Journal of the American Medical Association . , ... Dr. Brian Feagan, professor of medicine and director of ...
... Women on the hormone more than doubled the risk for ... Women who took a common form of estrogen as ... risk for certain types of benign breast disease compared with ... condition -- benign proliferative breast disease -- is relatively common ...
... mushroom (Ganoderma lucidum; Lingzhi) and green tea have long held ... countries, for the general promotion of health and long life ... studies have confirmed that both enhance the bodys immune functions ... types of cancer. , Now a new study ...
... frequently used illicit drugs by women during their childbearing ... during pregnancy, either alone or in combination with other ... There is strong evidence that THC, the main psychoactive ... abuse results in intrauterine growth retardation and that infants ...
Cached Medicine News:Health News:Cardinal Health to Announce Third-Quarter Results on May 1 2Health News:Cardinal Health to Announce Third-Quarter Results on May 1 3Health News:Genes' Influence on Fears Changes Over Time 2Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 2Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 3Health News:Estrogen Supplements May Raise Odds of Benign Breast Disease 2Health News:Extracts from reishi mushroom and green tea shows synergistic effect to slow sarcoma 2Health News:Marijuana increases alcohol toxicity in young rats 2
(Date:11/21/2014)... Nov. 20, 2014  The acceptance of two ... AAGL Global Congress demonstrates continued interest in the ... provide bowel control. One of the abstracts, presented by ... Division Chief of Urogynecology and Reconstructive Pelvic Surgery ... Award for Best Written Abstract on Urogynecology/Pelvic Floor ...
(Date:11/21/2014)... -- Oxis International, Inc. (OXIS) (OXI.PA) announced today the resignation ... J. Cataldo as Chief Executive Officer, and Steven ... Ken Eaton resigned his positions as Chief Executive ... International, Inc. to pursue new opportunities. Mr. ... of Oxis International, Inc. Mr. Cataldo will continue to serve ...
(Date:11/18/2014)... 18, 2014  NxStage ® Medical Inc. ... of innovative dialysis products , today announced ... dialyzer for the in-center, hemodialysis market.  Streamline Express ... designed to reduce the amount of labor required ... of touch point contamination sites.  The dialyzer enables ...
Breaking Medicine Technology:LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set 2
... with its Investor Day being held tomorrow in New York ... forward-looking earnings expectations for the fourth quarter of Fiscal Year ... for Fiscal Year 2013.  The Company reconfirmed ... and for all of Fiscal Year 2012, as issued in ...
... hospitals handed a resolute vote of confidence over ... enterprise clinical and financial system. Healthmark Regional Medical ... Kit Carson Memorial Hospital plan on leveraging the ... meeting the meaningful use requirements associated with the ...
Cached Medicine Technology:PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 2PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 3PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 4Hospitals Across the Country Select Prognosis HIS Enterprise Clinical and Financial System 2Hospitals Across the Country Select Prognosis HIS Enterprise Clinical and Financial System 3
... The Arx Ceramic ... innovative, biocompatible implants based ... technology that offers physicians ... to other synthetic and ...
CVC 9005 Hematocrit Calibration Verification Controls are materials used for verifying the calibration and linearity of hematocrit sensors in IRMA TRUpoint cartridges for systems using software versi...
... control material used for monitoring the performance of ... for specific use on Bayer analyzers that measure ... 270) and the AVOX Systems CO-Oximeters (4000 and ... the IRMA TRUpoint®. CC 527 is available in ...
RNA1c Control is an assayed quality control material used for monitoring the performance of Bayer DCA Analyzers that measure Hemoglobin A1c. It may be used on DCA 2000 and 2000+ analyzers....
Medicine Products: